Clinical trial NCT01589445 - References

Type 2 Diabetes Mellitus — Efficacy Study of Pioglitazone and Metformin and Association Between Pioglitazone Response and Peroxisome Proliferator-activated Receptor Gamma Gene Variants in Bangladeshi Type 2 Diabetes Mellitus Subjects

Citation(s)

•   Abdella N, Al Arouj M, Al Nakhi A, Al Assoussi A, Moussa M
  Non-insulin-dependent diabetes in Kuwait: prevalence rates and associated risk factors. Diabetes Res Clin Pract. 1998 Dec;42(3):187-96.
•   Abu Sayeed M, Banu A, Khan AR, Hussain MZ
  Prevalence of diabetes and hypertension in a rural population of Bangladesh. Diabetes Care. 1995 Apr;18(4):555-8.
•   Al-Shali KZ, House AA, Hanley AJ, Khan HM, Harris SB, Zinman B, Mamakeesick M, Fenster A, Spence JD, Hegele RA
  Genetic variation in PPARG encoding peroxisome proliferator-activated receptor gamma associated with carotid atherosclerosis. Stroke. 2004 Sep;35(9):2036-40. Epub 2004 Jul 29.
•   Alhossainy K
  (kalhossainy@gmail.com). As per our database. Parvin M (acmasuma@gmail.com) 21 July 2011.
•   Altshuler D, Hirschhorn JN, Klannemark M, Lindgren CM, Vohl MC, Nemesh J, Lane CR, Schaffner SF, Bolk S, Brewer C, Tuomi T, Gaudet D, Hudson TJ, Daly M, Groop L, Lander ES
  The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes. Nat Genet. 2000 Sep;26(1):76-80.
•   American Diabetes Association
  Diagnosis and classification of diabetes mellitus. Diabetes Care. 2005 Jan;28 Suppl 1:S37-42.
•   Armour T, Norris S, Brown D, Zhang X, Caspersen C
  Initiating and maintaining physical activity for type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2004.
•   Auwerx J
  PPARgamma, the ultimate thrifty gene. Diabetologia. 1999 Sep;42(9):1033-49. Review.
•   Avogaro A
  Insulin resistance: trigger or concomitant factor in the metabolic syndrome. Panminerva Med. 2006 Mar;48(1):3-12. Review.
•   Bailey CJ
  Treating insulin resistance in type 2 diabetes with metformin and thiazolidinediones. Diabetes Obes Metab. 2005 Nov;7(6):675-91. Review. Erratum in: Diabetes Obes Metab. 2005 Nov;7(6):769.
•   Barnett DM, Krall LP
  The History of diabetes. In Joslin's diabetes Mellitus, 14th ed. Boston MA. Lipincott William and Wilkins; 2005.
•   Beamer BA, Yen CJ, Andersen RE, Muller D, Elahi D, Cheskin LJ, Andres R, Roth J, Shuldiner AR
  Association of the Pro12Ala variant in the peroxisome proliferator-activated receptor-gamma2 gene with obesity in two Caucasian populations. Diabetes. 1998 Nov;47(11):1806-8.
•   Black C, Donnelly P, McIntyre L, Royle PL, Shepherd JP, Thomas S
  Meglitinide analogues for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2007 Apr 18;(2):CD004654. Review.
•   Blüher M, Lübben G, Paschke R
  Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes. Diabetes Care. 2003 Mar;26(3):825-31.
•   Boden G
  Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes. 1997 Jan;46(1):3-10. Review. Erratum in: Diabetes 1997 Mar;46(3):536.
•   Brown JB, Conner C, Nichols GA
  Secondary failure of metformin monotherapy in clinical practice. Diabetes Care. 2010 Mar;33(3):501-6. doi: 10.2337/dc09-1749. Epub 2009 Dec 29.
•   Cavaghan MK, Ehrmann DA, Byrne MM, Polonsky KS
  Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest. 1997 Aug 1;100(3):530-7.
•   Ceriello A, Johns D, Widel M, Eckland DJ, Gilmore KJ, Tan MH
  Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care. 2005 Feb;28(2):266-72. Erratum in: Diabetes Care. 2005 May;28(5):1272.
•   Charlotte E, Mathis G
  Inhaled insulin. Diabetes Health Center 2007, http://diabetes. webmd.com/inhaledinsulin.
•   Chuang LM, Hsiung CA, Chen YD, Ho LT, Sheu WH, Pei D, Nakatsuka CH, Cox D, Pratt RE, Lei HH, Tai TY
  Sibling-based association study of the PPARgamma2 Pro12Ala polymorphism and metabolic variables in Chinese and Japanese hypertension families: a SAPPHIRe study. Stanford Asian-Pacific Program in Hypertension and Insulin Resistance. J Mol Med (Berl). 2001 Nov;79(11):656-64.
•   Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance
  National Diabetes Data Group. Diabetes. 1979 Dec;28(12):1039-57.
•   Dabson M
  Experiments and observations on the urine in diabetes. Med Obs Inq 1776; 5: 298-316.
•   De Meyer J
  Sur la signification physiologique de la secretion interne du pancreas. Zbl Physiol 1904;18:S826.
•   de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M
  A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn. 2006 Jun;33(3):313-43. Epub 2006 Mar 22.
•   Deeb SS, Fajas L, Nemoto M, Pihlajamäki J, Mykkänen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J
  A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet. 1998 Nov;20(3):284-7.
•   DeFronzo RA, Ferrannini E
  Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. Diabetes Care. 1991 Mar;14(3):173-94. Review.
•   DeFronzo RA, Goodman AM
  Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med. 1995 Aug 31;333(9):541-9.
•   DeFronzo RA, Tobin JD, Andres R
  Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol. 1979 Sep;237(3):E214-23.
•   DeFronzo RA
  Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes. 1988 Jun;37(6):667-87. Review.
•   DeFronzo RA
  Pathogenesis of type 2 diabetes: metabolic and molecular implication for identifying diabetes genes. In: American Diabetes Association, eds (Annual Review Of Diabetes), AlexandriaVA: American Diabetes 1998; 1-93.
•   Diabetes Statistics -Diabetes help
  http://www.diabetes.org.uk/Professionals/ Publications-reports-and-resources/Reports-statistics-and-case-studies/Reports/ Diabetes-prevalance-2010
•   Diabetic Association of Bangladesh
  Statistical Year Book. July 2009-June 2010; p 250. web version is available at www.dab-bd.org.
•   Diani AR, Sawada G, Wyse B, Murray FT, Khan M
  Pioglitazone preserves pancreatic islet structure and insulin secretory function in three murine models of type 2 diabetes. Am J Physiol Endocrinol Metab. 2004 Jan;286(1):E116-22. Epub 2003 Oct 7.
•   Dubuquoy L, Dharancy S, Nutten S, Pettersson S, Auwerx J, Desreumaux P
  Role of peroxisome proliferator-activated receptor gamma and retinoid X receptor heterodimer in hepatogastroenterological diseases. Lancet. 2002 Nov 2;360(9343):1410-8. Review.
•   Dunn C, Curran MP
  Inhaled human insulin (Exubera): a review of its use in adult patients with diabetes mellitus. Drugs. 2006;66(7):1013-32. Review.
•   Ek J, Andersen G, Urhammer SA, Hansen L, Carstensen B, Borch-Johnsen K, Drivsholm T, Berglund L, Hansen T, Lithell H, Pedersen O
  Studies of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor-gamma2 (PPAR-gamma2) gene in relation to insulin sensitivity among glucose tolerant caucasians. Diabetologia. 2001 Sep;44(9):1170-6.
•   Ek J, Urhammer SA, Sørensen TI, Andersen T, Auwerx J, Pedersen O
  Homozygosity of the Pro12Ala variant of the peroxisome proliferation-activated receptor-gamma2 (PPAR-gamma2): divergent modulating effects on body mass index in obese and lean Caucasian men. Diabetologia. 1999 Jul;42(7):892-5.
•   Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz Md, Moller DE, Berger J
  Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun. 1996 Jul 16;224(2):431-7.
•   Fajas L, Auboeuf D, Raspé E, Schoonjans K, Lefebvre AM, Saladin R, Najib J, Laville M, Fruchart JC, Deeb S, Vidal-Puig A, Flier J, Briggs MR, Staels B, Vidal H, Auwerx J
  The organization, promoter analysis, and expression of the human PPARgamma gene. J Biol Chem. 1997 Jul 25;272(30):18779-89.
•   Ferré P
  The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes. 2004 Feb;53 Suppl 1:S43-50. Review.
•   Flórez H
  [Steps toward the primary prevention of type II diabetes mellitus. Various epidemiological considerations]. Invest Clin. 1997 Mar;38(1):39-52. Review. Spanish.
•   Garvey WT, Olefsky JM, Griffin J, Hamman RF, Kolterman OG
  The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus. Diabetes. 1985 Mar;34(3):222-34.
•   Gerich JE, Smith TM
  beta-cell defects and pancreatic abnormalities in type 2 diabetes. In: Textbook of Diabetes, 3rd ed, Pickup JC & Williams G, Eds, Blackwell Science 23; 2003: 1-23.11.
•   Gimenez-Perez G, Gonzalez-Clemente JM, Mauricio D
  Lifestyle interventions for preventing type 2 diabetes mellitus. Cochrane Database of Systematic Reviews 2001.
•   Globerman H, Zauberman Y, Makarov T, Beamer BA, Yen CJ, Shuldiner AR, Harel C, Karnieli E
  Analysis of the peroxisome proliferator activated receptor gamma (PPARgamma) gene in HAIRAN syndrome with obesity. Clin Endocrinol (Oxf). 2000 Apr;52(4):479-85.
•   Goodman & Gilmans'
  The Pharmacological basis of Therapeutics. 10th ed. International Edition, McGraw Hill; 2001: p1701, 1704, 1706.
•   Gouda HN, Sagoo GS, Harding AH, Yates J, Sandhu MS, Higgins JP
  The association between the peroxisome proliferator-activated receptor-gamma2 (PPARG2) Pro12Ala gene variant and type 2 diabetes mellitus: a HuGE review and meta-analysis. Am J Epidemiol. 2010 Mar 15;171(6):645-55. doi: 10.1093/aje/kwp450. Epub 2010 Feb 23. Review.
•   Greene ME, Blumberg B, McBride OW, Yi HF, Kronquist K, Kwan K, Hsieh L, Greene G, Nimer SD
  Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr. 1995;4(4-5):281-99.
•   Gyas M
  Interviewed by: Parvin M. 16 October 2011.
•   Hamman RF
  Genetic and environmental determinants of non-insulin-dependent diabetes mellitus (NIDDM). Diabetes Metab Rev. 1992 Dec;8(4):287-338. Review.
•   Hara K, Yamauchi T, Kubota N, Tobe K, Yamazaki T, Nagai R, Kadowaki T
  [The role of PPARgamma in the onset of type 2 diabetes]. Nihon Yakurigaku Zasshi. 2003 Oct;122(4):317-24. Review. Japanese.
•   Health Survey for England
  http://www.heartstats.org/datapage.
•   Holstein A, Seeringer A, Kovacs P
  Therapy With Oral Antidiabetic Drugs: Applied pharmacogenetics. British Journal of Diabetes & Vascular Disease 2011;11:10. DOI: 10.1177/1474651410397583 (accessed on 20 October 2011).
•   Hundal RS, Krssak M, Dufour S, Laurent D, Lebon V, Chandramouli V, Inzucchi SE, Schumann WC, Petersen KF, Landau BR, Shulman GI
  Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes. 2000 Dec;49(12):2063-9.
•   Ito H, Ohno Y, Yamauchi T, Kawabata Y, Ikegami H
  Efficacy and safety of metformin for treatment of type 2 diabetes in elderly Japanese patients. Geriatr Gerontol Int. 2011 Jan;11(1):55-62. doi: 10.1111/j.1447-0594.2010.00635.x.
•   Iwata E, Matsuda H, Fukuda T, Fukuen S, Motomura T, Igarashi T, Yamamoto I, Azuma J
  Mutations of the peroxisome proliferator-activated receptor gamma (PPAR gamma) gene in a Japanese population : the Pro12Ala mutation in PPAR gamma 2 is associated with lower concentrations of serum total and non-HDL cholesterol. Diabetologia. 2001 Oct;44(10):1354-5.
•   Kahn CR
  Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes. 1994 Aug;43(8):1066-84. Review.
•   Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, Kravitz BG, Lachin JM, O'Neill MC, Zinman B, Viberti G; ADOPT Study Group
  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med. 2006 Dec 7;355(23):2427-43. Epub 2006 Dec 4. Erratum in: N Engl J Med. 2007 Mar 29;356(13):1387-8.
•   Kahn SE, Porte DJ
  The pathophysiology of type II (noninsulindependent) diabetes mellitus: implications for treatment. In: Porte D Jr, Sherwin RS editor(s). Ellenberg & Rifkin's Diabetes Mellitus. 5th ed. Stamford, Conneticut (U.S.A.): Appleton & Lange, 1997.
•   Kain K, Catto Aj
  Trans-Cultural Medicine: Insulin Resistance Syndrome In South Asians. The British Journal of Diabetes & Vascular Disease 2002; 2: 398.
•   Kaku K, Tajima N, Kawamori R
  Melbin observational research (MORE) study of metformin therapy in patients with type 2 diabetes mellitus. J Japan Diab Soc 2006; 49: 325-331 (in Japanese).
•   Kaku K
  Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. Curr Med Res Opin. 2009 May;25(5):1111-9. doi: 10.1185/03007990902820816 .
•   Kang ES, Park SY, Kim HJ, Kim CS, Ahn CW, Cha BS, Lim SK, Nam CM, Lee HC
  Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes. Clin Pharmacol Ther. 2005 Aug;78(2):202-8.
•   Katsilambros N, Tentolouris N
  Type 2 diabetes: an overview. In: Textbook of Diabetes, 3rd ed. Pickup JC and Williams G, Eds, Blackwell Science; 2003: pp 4.1-4.19.
•   Kim H, Haluzik M, Asghar Z, Yau D, Joseph JW, Fernandez AM, Reitman ML, Yakar S, Stannard B, Heron-Milhavet L, Wheeler MB, LeRoith D
  Peroxisome proliferator-activated receptor-alpha agonist treatment in a transgenic model of type 2 diabetes reverses the lipotoxic state and improves glucose homeostasis. Diabetes. 2003 Jul;52(7):1770-8.
•   Koch M, Rett K, Maerker E, Volk A, Haist K, Deninger M, Renn W, Häring HU
  The PPARgamma2 amino acid polymorphism Pro 12 Ala is prevalent in offspring of Type II diabetic patients and is associated to increased insulin sensitivity in a subgroup of obese subjects. Diabetologia. 1999 Jun;42(6):758-62.
•   Kolterman OG, Gray RS, Shapiro G, Scarlett JA, Griffin J, Olefsky JM
  The acute and chronic effects of sulfonylurea therapy in type II diabetic subjects. Diabetes. 1984 Apr;33(4):346-54.
•   Krall LP
  The wide world of diabetes. In: World book of diabetes in practice. Krall LP. (ed) v2 Amsterdam: Elsevier Science publishing; 1986.
•   Kubo K
  Effect of pioglitazone on blood proinsulin levels in patients with type 2 diabetes mellitus. Endocr J. 2002 Jun;49(3):323-8.
•   Laakso M
  Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes. 1999 May;48(5):937-42. Review.
•   Lang DA, Matthews DR, Burnett M, Turner RC
  Brief, irregular oscillations of basal plasma insulin and glucose concentrations in diabetic man. Diabetes. 1981 May;30(5):435-9.
•   Langenfeld MR, Forst T, Hohberg C, Kann P, Lübben G, Konrad T, Füllert SD, Sachara C, Pfützner A
  Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005 May 17;111(19):2525-31. Epub 2005 May 9.
•   Lasker SP, McLachlan CS, Wang L, Ali SMK , Jelinek HF
  Discovery, treatment and management of diabetes (Review Article). Journal of Diabetology Feb 2010; 1:1 http://www.journalofdiabetology.org/
•   Li J, Tian H, Ren Y, et al
  Effect of pioglitazone on first phase insulin secretion in type 2 diabetes mellitus and impaired glucose tolerance. Diabetes. 2003 (Abstract No 1212-P); 52 : A281.
•   Lillioja S, Mott DM, Zawadzki JK, Young AA, Abbott WG, Knowler WC, Bennett PH, Moll P, Bogardus C
  In vivo insulin action is familial characteristic in nondiabetic Pima Indians. Diabetes. 1987 Nov;36(11):1329-35.
•   Lohmueller KE, Pearce CL, Pike M, Lander ES, Hirschhorn JN
  Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease. Nat Genet. 2003 Feb;33(2):177-82. Epub 2003 Jan 13.
•   Luzi L, DeFronzo RA
  Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. Am J Physiol. 1989 Aug;257(2 Pt 1):E241-6.
•   MacCracken J, Hoel D
  From ants to analogues. Puzzles and promises in diabetes management. Postgrad Med. 1997 Apr;101(4):138-40, 143-5, 149-50.
•   Mahtab H, Khan AR, Latif ZA, Pathan F, Ahmed T
  Guideline for care of Type 2 Diabetes Mellitus in Bangladesh. BIRDEM Clinical Research Group Publishing 2003.
•   Masugi J, Tamori Y, Mori H, Koike T, Kasuga M
  Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis. Biochem Biophys Res Commun. 2000 Feb 5;268(1):178-82.
•   Mathur SK, Rathore R, Chandra S, Sharma BB, Sharma L, Mathur P, Mathur M
  Primary pioglitazone failure in Asian Indian diabetics is not related to common Pro12Ala polymorph of PPAR-gamma gene. Indian J Physiol Pharmacol. 2009 Apr-Jun;53(2):175-80.
•   Matthaei S, Stumvoll M, Kellerer M, Häring HU
  Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev. 2000 Dec;21(6):585-618. Review.
•   Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G
  Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005 Mar-Apr;21(2):167-74.
•   Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC
  Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985 Jul;28(7):412-9.
•   Mayerson AB, Hundal RS, Dufour S, Lebon V, Befroy D, Cline GW, Enocksson S, Inzucchi SE, Shulman GI, Petersen KF
  The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes. 2002 Mar;51(3):797-802.
•   McKeigue PM, Miller GJ, Marmot MG
  Coronary heart disease in south Asians overseas: a review. J Clin Epidemiol. 1989;42(7):597-609. Review.
•   McKeigue PM, Shah B, Marmot MG
  Relation of central obesity and insulin resistance with high diabetes prevalence and cardiovascular risk in South Asians. Lancet. 1991 Feb 16;337(8738):382-6.
•   Meriden T
  Progress with thiazolidinediones in the management of type 2 diabetes mellitus. Clin Ther. 2004 Feb;26(2):177-90. Review.
•   Metformin
  http://en.wikipedia.org/wiki/Metformin (accessed on 20 October 2011)
•   Michael J, Fowler MD
  Microvascular and Macrovascular Complications of Diabetes. Clinical Diabetes 2008; 26 : 77-82.
•   Misso ML, Egberts KJ, Page M, O'Connor D, Shaw J
  Continuous subcutaneous insulin infusion (CSII) versus multiple insulin injections for type 1 diabetes mellitus. Cochrane Database Syst Rev. 2010 Jan 20;(1):CD005103. doi: 10.1002/14651858.CD005103.pub2. Review.
•   Miyazaki Y, Mahankali A, Matsuda M, Mahankali S, Hardies J, Cusi K, Mandarino LJ, DeFronzo RA
  Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91.
•   Miyazaki Y, Matsuda M, DeFronzo RA
  Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care. 2002 Mar;25(3):517-23.
•   Mori H, Ikegami H, Kawaguchi Y, Seino S, Yokoi N, Takeda J, Inoue I, Seino Y, Yasuda K, Hanafusa T, Yamagata K, Awata T, Kadowaki T, Hara K, Yamada N, Gotoda T, Iwasaki N, Iwamoto Y, Sanke T, Nanjo K, Oka Y, Matsutani A, Maeda E, Kasuga M
  The Pro12 -->Ala substitution in PPAR-gamma is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes. Diabetes. 2001 Apr;50(4):891-4.
•   Moser M, Sowers JR
  Clinical Management of Cardiovascular Risk Factors in Diabetes. 4th ed. USA: Professional Communications Publishing; 2011 : p 230.
•   Nagasaka S, Aiso Y, Yoshizawa K, Ishibashi S
  Comparison of pioglitazone and metformin efficacy using homeostasis model assessment. Diabet Med. 2004 Feb;21(2):136-41.
•   National Service Framework for Diabetes: Standards http:// www
  technology adoptioncentre.nhs.uk/assets/_files/documents/mar_10/nhs__1268044698_Diabetes_NSF.pdf
•   Newman B, Selby JV, King MC, Slemenda C, Fabsitz R, Friedman GD
  Concordance for type 2 (non-insulin-dependent) diabetes mellitus in male twins. Diabetologia. 1987 Oct;30(10):763-8.
•   Nicklas BJ, van Rossum EF, Berman DM, Ryan AS, Dennis KE, Shuldiner AR
  Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain. Diabetes. 2001 Sep;50(9):2172-6.
•   Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H
  Dietary advice for the prevention of type 2 diabetes mellitus in adults. Cochrane Database Syst Rev. 2008 Jul 16;(3):CD005102. doi: 10.1002/14651858.CD005102.pub2. Review. Update in: Cochrane Database Syst Rev. 2016;1:CD005102.
•   Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators
  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. JAMA. 2008 Apr 2;299(13):1561-73. doi: 10.1001/jama.299.13.1561. Epub 2008 Mar 31.
•   O'Moore-Sullivan TM, Prins JB
  Thiazolidinediones and type 2 diabetes: new drugs for an old disease. Med J Aust. 2002 Apr 15;176(8):381-6. Review. Erratum in: Med J Aust 2002 Oct 7;177(7):396.
•   O'Rahilly S, Hattersley A, Vaag A, Gray H
  Insulin resistance as the major cause of impaired glucose tolerance: a self-fulfilling prophesy? Lancet. 1994 Aug 27;344(8922):585-9.
•   O'Rahilly SP, Nugent Z, Rudenski AS, Hosker JP, Burnett MA, Darling P, Turner RC
  Beta-cell dysfunction, rather than insulin insensitivity, is the primary defect in familial type 2 diabetes. Lancet. 1986 Aug 16;2(8503):360-4.
•   Oh EY, Min KM, Chung JH, Min YK, Lee MS, Kim KW, Lee MK
  Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects. J Clin Endocrinol Metab. 2000 May;85(5):1801-4.
•   Olefsky JM
  Insulin resistance. In: Rifkin H, porte D Jr, eds. Ellenberg and Rifkin's diabetes mellitus: theory and practice. NewYork: Elsvier 1997: 513-52.
•   Olefsky JM
  Treatment of insulin resistance with peroxisome proliferator-activated receptor gamma agonists. J Clin Invest. 2000 Aug;106(4):467-72. Review.
•   Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX, Lin J, Xiao JZ, Cao HB, Liu PA, Jiang XG, Jiang YY, Wang JP, Zheng H, Zhang H, Bennett PH, Howard BV
  Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. The Da Qing IGT and Diabetes Study. Diabetes Care. 1997 Apr;20(4):537-44.
•   Paracchini V, Pedotti P, Taioli E
  Genetics of leptin and obesity: a HuGE review. Am J Epidemiol. 2005 Jul 15;162(2):101-14. Epub 2005 Jun 22. Review.
•   Parikh H, Groop L
  Candidate genes for type 2 diabetes. Rev Endocr Metab Disord. 2004 May;5(2):151-76. Review.
•   Patlak M
  New weapons to combat an ancient disease: treating diabetes. FASEB J. 2002 Dec;16(14):1853.
•   Perriello G, Misericordia P, Volpi E, Santucci A, Santucci C, Ferrannini E, Ventura MM, Santeusanio F, Brunetti P, Bolli GB
  Acute antihyperglycemic mechanisms of metformin in NIDDM. Evidence for suppression of lipid oxidation and hepatic glucose production. Diabetes. 1994 Jul;43(7):920-8.
•   Pickup JC, Willium G
  The history of diabetes mellitus. In Textbook of diabetes. 3rd ed. Vol-1.Oxford London: Blackwell Science Limited; 2003.
•   Polonsky KS, Given BD, Hirsch LJ, Tillil H, Shapiro ET, Beebe C, Frank BH, Galloway JA, Van Cauter E
  Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med. 1988 May 12;318(19):1231-9.
•   Power AC
  Diabetes mellitus.In: KasperDL, Fauci AS, Longo DL,Braunwald E, Hauser SL, Jameson JL (Eds). Harrison's Principles of Internal Medicine, 16th ed. McGraw-Hill; 2005: 2152-79.
•   Ramachandran A, Snehalatha C, Latha E, Manoharan M, Vijay V
  Impacts of urbanisation on the lifestyle and on the prevalence of diabetes in native Asian Indian population. Diabetes Res Clin Pract. 1999 Jun;44(3):207-13.
•   Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V; Indian Diabetes Prevention Programme (IDPP)
  The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006 Feb;49(2):289-97. Epub 2006 Jan 4.
•   Rasouli N, Raue U, Miles LM, Lu T, Di Gregorio GB, Elbein SC, Kern PA
  Pioglitazone improves insulin sensitivity through reduction in muscle lipid and redistribution of lipid into adipose tissue. Am J Physiol Endocrinol Metab. 2005 May;288(5):E930-4. Epub 2005 Jan 4.
•   Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim SH
  Pioglitazone for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006 Oct 18;(4):CD006060. Review.
•   Richter B, Neises G
  'Human' insulin versus animal insulin in people with diabetes mellitus. Cochrane Database Syst Rev. 2005 Jan 25;(1):CD003816. Review.
•   Rizza RA, Mandarino LJ, Gerich JE
  Mechanism and significance of insulin resistance in non-insulin-dependent diabetes mellitus. Diabetes. 1981 Dec;30(12):990-5.
•   Roberts D, Van NW, Chang H, Pohula W, MCheang, Moffatt M, et al
  Glargine versus other basal insulins (NPH, Lente, or Ultralente) for the treatment of type 1 diabetes mellitus. Cochrane Database of Systematic Reviews 2005.
•   Saenz A, Fernandez-Esteban I, Mataix A, Ausejo M, Roque M, Moher D
  Metformin monotherapy for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2005 Jul 20;(3):CD002966. Review. Update in: Cochrane Database Syst Rev. 2015;9:CD002966.
•   Salpeter S, Greyber E, Pasternak G, Salpeter E
  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev. 2003;(2):CD002967. Review. Update in: Cochrane Database Syst Rev. 2006;(1):CD002967.
•   Sayeed MA, Banu A, Haq JA, Khanam PA, Mahtab H, Azad Khan AK
  Prevalence of hypertension in Bangladesh: effect of socioeconomic risk factor on difference between rural and urban community. Bangladesh Med Res Counc Bull. 2002 Apr;28(1):7-18.
•   Sayeed MA, Hussain MZ, Banu A, Rumi MA, Azad Khan AK
  Prevalence of diabetes in a suburban population of Bangladesh. Diabetes Res Clin Pract. 1997 Jan;34(3):149-55.
•   Sayeed MA, Mahtab H, Khanam PA, Latif ZA, Banu A, Khan AK
  Prevalence of diabetes and impaired fasting glucose in urban population of Bangladesh. Bangladesh Med Res Counc Bull. 2007 Apr;33(1):1-12.
•   Schernthaner G, Matthews DR, Charbonnel B, Hanefeld M, Brunetti P; Quartet [corrected] Study Group
  Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial. J Clin Endocrinol Metab. 2004 Dec;89(12):6068-76. Erratum in: J Clin Endocrinol Metab. 2005 Feb;90(2):746.
•   Seda O, Sedová L
  PPARs: molecular targets in the pharmacogenomics era. Prague Med Rep. 2004;105(3):223-36. Review.
•   Seidell JC, Hautvast JG, Deurenberg P
  Overweight: fat distribution and health risks. Epidemiological observations. A review. Infusionstherapie. 1989 Dec;16(6):276-81. Review.
•   Shaw JE, Sicree RA, Zimmet PZ
  Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract. 2010 Jan;87(1):4-14. doi: 10.1016/j.diabres.2009.10.007. Epub 2009 Nov 6.
•   Sherwin RS, Hendler RG, Felig P
  Effect of diabetes mellitus and insulin on the turnover and metabolic response to ketones in man. Diabetes. 1976 Sep;25(9):776-84.
•   Shihara N, Kitaoka M, Inagaki N, Kadowaki T, Koumoto S, Satoh J, Terauchi Y, Nunoi K, Yamada Y, Sakamaki H, Seino Y
  Randomized controlled trial of single-agent glimepiride and pioglitazone in Japanese patients with type 2 diabetes: A comparative study. J Diabetes Investig. 2011 Oct 7;2(5):391-8. doi: 10.1111/j.2040-1124.2011.00115.x.
•   Silink M
  The diabetes epidemic: The case for a resolution on diabetes. Diabetic Endocrine Journal 2006; 34:3-4.
•   Singh RB, Bajaj S, Niaz MA, Rastogi SS, Moshiri M
  Prevalence of type 2 diabetes mellitus and risk of hypertension and coronary artery disease in rural and urban population with low rates of obesity. Int J Cardiol. 1998 Sep 1;66(1):65-72.
•   Smith U
  Pioglitazone: mechanism of action. Int J Clin Pract Suppl. 2001 Sep;(121):13-8. Review.
•   Snitker S, Watanabe RM, Ani I, Xiang AH, Marroquin A, Ochoa C, Goico J, Shuldiner AR, Buchanan TA; Troglitazone in Prevention of Diabetes (TRIPOD) study
  Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study. Diabetes Care. 2004 Jun;27(6):1365-8.
•   Spiegelman BM
  PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes. 1998 Apr;47(4):507-14. Review.
•   Staels B, Fruchart JC
  Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes. 2005 Aug;54(8):2460-70. Review.
•   Stuart AR
  Insulin and related medication. In Pharmacologic aspects of nursing. Paghiro, AM and Pagliaro, LA (eds). USA. The C.V. Mosby Company; 1988.
•   Stumvoll M, Goldstein BJ, van Haeften TW
  Type 2 diabetes: principles of pathogenesis and therapy. Lancet. 2005 Apr 9-15;365(9467):1333-46. Review.
•   Stumvoll M, Häring H
  The peroxisome proliferator-activated receptor-gamma2 Pro12Ala polymorphism. Diabetes. 2002 Aug;51(8):2341-7. Review.
•   Stumvoll M, Wahl HG, Löblein K, Becker R, Machicao F, Jacob S, Häring H
  Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-gamma2 gene is associated with increased antilipolytic insulin sensitivity. Diabetes. 2001 Apr;50(4):876-81.
•   Summerson JH, Bell RA, Konen JC
  Coronary heart disease risk factors in black and white patients with non-insulin-dependent diabetes mellitus. Ethn Health. 1996 Mar;1(1):9-20.
•   Tan MH, Glazer NB, Johns D, Widel M, Gilmore KJ
  Pioglitazone as monotherapy or in combination with sulfonylurea or metformin enhances insulin sensitivity (HOMA-S or QUICKI) in patients with type 2 diabetes. Curr Med Res Opin. 2004 May;20(5):723-8.
•   Taylor SI, Accili D, Imai Y
  Insulin resistance or insulin deficiency. Which is the primary cause of NIDDM? Diabetes. 1994 Jun;43(6):735-40. Review.
•   Thiazolidinedione http://en
  wikipedia.org/wiki/Thiazolidinedione
•   Thomas DE, Elliott EJ, Naughton GA
  Exercise for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD002968. Review.
•   Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C, Scherer PE, Hawkins M
  Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes. 2004 Jun;53(6):1621-9. Erratum in: Diabetes. 2005 Feb;54(2):587.
•   Trivedi B, Mazumdar JD, Bhatt, Hemavathi KG
  Effect of Shilajit on blood glucose and lipid profile in alloxan-induced diabetic rats. Indian J Pharmacol 2004; 36: 373-376.
•   U
  K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group. Diabetes. 1995 Nov;44(11):1249-58. Erratum in: Diabetes 1996 Nov;45(11):1655.
•   Vigouroux C, Fajas L, Khallouf E, Meier M, Gyapay G, Lascols O, Auwerx J, Weissenbach J, Capeau J, Magré J
  Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes. Diabetes. 1998 Mar;47(3):490-2.
•   Vilar L, Canadas V, Arruda MJ, Arahata C, Agra R, Pontes L, Montenegro L, Vilar CF, Silva LM, Albuquerque JL, Gusmão A
  Comparison of metformin, gliclazide MR and rosiglitazone in monotherapy and in combination for type 2 diabetes. Arq Bras Endocrinol Metabol. 2010 Mar;54(3):311-8.
•   Von Mering J, Minowski O
  Diabetes mellitus nach pancreas extripation. Arch Exper Path Pharmacol Leipzig 1890; 26: 371-87.
•   Werman A, Hollenberg A, Solanes G, Bjorbaek C, Vidal-Puig AJ, Flier JS
  Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential activity of PPARgamma1 and -2 isoforms and influence of insulin. J Biol Chem. 1997 Aug 8;272(32):20230-5.
•   West KM, Kalbfleisch JM
  Glucose tolerance, nutrition, and diabetes in Uruguay, Venezuela, Malaya, and East Pakistan. Diabetes. 1966 Jan;15(1):9-18.
•   WHO Expert Consultation
  Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet. 2004 Jan 10;363(9403):157-63. Review. Erratum in: Lancet. 2004 Mar 13;363(9412):902.
•   Wild S, Roglic G, Green A, Sicree R, King H
  Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care. 2004 May;27(5):1047-53.
•   World Health Organization
  Definition, Diagnosis, Classification of Diabetes Mellitus and its Complications. Geneva: WHO 1999. Report of a WHO Consultation. Part1: Diagnosis and Classification of Diabetes Mellitus.
•   Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT
  The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review. J Intern Med. 2004 Jul;256(1):1-14. Review.
•   Yki-Järvinen H
  Thiazolidinediones. N Engl J Med. 2004 Sep 9;351(11):1106-18. Review.
•   Yoon KH, Shin JA, Kwon HS, Lee SH, Min KW, Ahn YB, Yoo SJ, Ahn KJ, Park SW, Lee KW, Sung YA, Park TS, Kim MS, Kim YK, Nam MS, Kim HS, Park IeB, Park JS, Woo JT, Son HY
  Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study. Diabetes Metab J. 2011 Feb;35(1):26-33. doi: 10.4093/dmj.2011.35.1.26. Epub 2011 Feb 28.
•   Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE
  Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest. 2001 Oct;108(8):1167-74.
•   Zimmet P, Alberti KG, Shaw J
  Global and societal implications of the diabetes epidemic. Nature. 2001 Dec 13;414(6865):782-7. Review.
•   Zinnat R
  Role of Insulin Defficiency and Insulin Resistance in the Pathogenesis of Type 2 Diabetes in Young Bangladesh Subjects. M.Phil thesis. Bangladesh Institute of Research and Rehabilitation in Diabetes, Endocrine and Metabolic Disorders; 1999.

Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.

Details for clinical trial NCT01589445